Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Dementia screening sits at the center of this dementia and brain health question.
The AD8 is a brief, eight-question screening tool designed to identify the early signs of dementia and mild cognitive impairment. Developed by researchers at Washington University in St. Louis’s Knight Alzheimer Disease Research Center, the AD8—which stands for “The Eight-item Informant Interview to Differentiate Aging and Dementia”—helps distinguish between normal age-related memory changes and actual cognitive decline that warrants further medical evaluation. Unlike casual memory lapses that most older adults experience, the AD8 targets specific patterns that suggest something more serious may be developing.
For example, when a family member notices that their 75-year-old parent, who has always paid bills reliably, now forgets to pay them or pays them twice, that kind of functional change is exactly what the AD8 is designed to catch. The tool works by asking an informant—typically a family member or close caregiver who knows the person well—to answer questions about changes they’ve observed in the person’s memory, orientation, judgment, and ability to handle daily tasks. Because the AD8 relies on observations from someone close to the person, it captures real-world changes that might not show up in a doctor’s office. The screening takes just minutes to complete, makes no special equipment necessary, and provides a quick signal about whether a comprehensive dementia evaluation should be pursued.
Table of Contents
- The History and Development of AD8 Dementia Screening
- How the AD8 Works and What It Measures
- Diagnostic Accuracy and Reliability Data
- Interpreting AD8 Scores and Cut Points
- Critical Limitations of the AD8 Screening Tool
- When and Where the AD8 Is Used in Clinical Practice
- The Future of Cognitive Screening and the AD8’s Role
- Conclusion
The History and Development of AD8 Dementia Screening
The AD8 emerged from decades of research into how dementia develops and manifests in everyday life. Researchers at Washington University recognized that families often notice cognitive changes before formal medical testing detects them, and they wanted to create a standardized way to capture those observations. By focusing on informant-based assessment rather than direct patient testing, the AD8 taps into the intimate knowledge that spouses, adult children, and close caregivers have about a person’s cognitive patterns and functional abilities over time.
The instrument has been extensively validated across diverse populations and continues to be refined with new research. A 2024 study published in PLOS ONE reexamined the AD8’s performance in Turkish geriatric outpatients and confirmed its reliability for detecting both dementia and mild cognitive impairment across different cultural and healthcare settings. This ongoing validation work matters because it ensures the tool works well for people with different backgrounds and healthcare experiences, not just the populations where it was first developed. The consistency of AD8’s performance across these varied groups is one reason it has become standard in many dementia evaluation protocols worldwide.
How the AD8 Works and What It Measures
The AD8 consists of eight specific questions that focus on observable changes in cognitive function and daily living skills. These questions assess memory problems (Has the person noticed that the person has memory problems?), orientation to time (Does the person have trouble with the date or day of the week?), judgment and decision-making (Has the person had problems handling finances?), and ability to perform familiar tasks (Does the person have trouble with a familiar recipe, household task, or simple job that they’ve done for years?). Each question is answered by the informant based on whether they’ve noticed a change in the person’s abilities, not whether the person has the ability itself—the focus is on observable decline, not absolute performance.
Because the AD8 relies on changes that someone close to the person has noticed, it’s particularly good at capturing subtle shifts that might not be apparent during a brief doctor’s visit. A person might appear fine during a 10-minute office examination, but a spouse who lives with them knows they’ve been repeating the same questions multiple times in a single conversation or forgetting important appointments. This informant-based approach is both a strength and a limitation: it provides real-world insight but depends on having someone available who knows the person well and can reliably report changes. In cases where no close informant is available, or when the informant’s own memory is questionable, the AD8 may be less effective.
Diagnostic Accuracy and Reliability Data
The AD8 has demonstrated strong diagnostic performance across multiple research studies. Sensitivity—the ability to correctly identify people with cognitive impairment—exceeds 84%, meaning the tool catches at least 84 out of 100 people who truly have dementia or mild cognitive impairment. Specificity, the ability to correctly identify people without cognitive problems, exceeds 80%, which means relatively few people without actual cognitive impairment will be incorrectly flagged. The positive predictive value, indicating the likelihood that someone scoring positive actually has cognitive impairment, is greater than 85%, and the negative predictive value (the likelihood that someone scoring negative is truly unimpaired) exceeds 70%.
Perhaps most importantly, the AD8 correlates strongly with the Clinical Dementia Rating scale, the gold standard instrument for assessing dementia severity, with a correlation coefficient of r = 0.75. This high correlation indicates that the AD8’s quick assessment aligns well with more comprehensive evaluations that take much longer to administer. For example, a person who scores high on the AD8 will likely also receive a CDR rating that confirms cognitive impairment, making the brief eight-item screening a reliable predictor of whether more detailed testing is warranted. These performance metrics are why the AD8 is recommended by organizations including the Hartford Institute for Geriatric nursing and is used in clinical settings ranging from primary care offices to specialty memory clinics.
Interpreting AD8 Scores and Cut Points
The AD8 uses a simple scoring system: a score of 0 to 1 indicates normal cognition, while a score of 2 or greater suggests impairment in cognition that warrants further evaluation. This is a binary threshold rather than a sliding scale, making the tool straightforward to interpret and act upon. When someone scores 2 or higher, the recommendation is not to diagnose dementia based on that score alone, but rather to proceed with a comprehensive cognitive and medical evaluation by a physician or neuropsychologist. Think of the AD8 as a red traffic light that says “stop and investigate further,” not as a final diagnosis.
The cut point of 2 has been carefully chosen through validation research to optimize the balance between sensitivity and specificity. It’s low enough that people with genuine cognitive impairment are rarely missed, but high enough that normal aging changes don’t trigger false alarms. However, it’s important to recognize that a single false answer or misunderstanding of a question can sometimes push a score from 1 to 2, and a skilled interviewer will want to clarify any responses that seem ambiguous. Some AD8 administration protocols also include the option of re-administering the tool or discussing individual questions in more detail if the initial score falls right at the cut point.
Critical Limitations of the AD8 Screening Tool
The most important limitation of the AD8 is something that must be stated clearly: it is a screening tool only and is insufficient to diagnose a dementing disorder. A positive AD8 score is a signal that something may be wrong, but it is not a diagnosis. Many conditions beyond dementia can cause cognitive changes—thyroid disease, vitamin B12 deficiency, depression, medication side effects, and sleep disorders, for example—and only a comprehensive medical evaluation can determine the true cause. This distinction is crucial because families sometimes become alarmed when a loved one scores positive on the AD8, fearing an immediate dementia diagnosis, when in fact the tool is simply indicating that further investigation is needed.
Another significant limitation is that the AD8 depends entirely on the informant’s knowledge, memory, and willingness to report changes accurately. A person with early mild cognitive impairment might have no close family member or caregiver to observe their changes, making the AD8 impossible to administer. Additionally, in cases where the informant themselves has memory problems or where there are family dynamics that might bias reporting—such as a family member who downplays symptoms or one who exaggerates minor changes—the AD8 results may be less reliable. The tool also cannot be used if no one is available who has known the person well for an extended period to notice changes over time.
When and Where the AD8 Is Used in Clinical Practice
The AD8 typically appears as part of the initial cognitive screening process in primary care settings, memory clinics, geriatric practices, and some long-term care facilities. A primary care physician might administer the AD8 during an annual wellness visit for an older adult, or a family might bring the tool to an appointment because they’re concerned about a parent’s memory. If the score is 2 or greater, the clinician will usually recommend more comprehensive testing, which might include a longer cognitive battery such as the Montreal Cognitive Assessment, the Mini-Cog, or neuropsychological testing, along with blood work, imaging, and a detailed history. The AD8 is valuable precisely because it’s quick enough to be practical in busy clinical settings while still carrying meaningful predictive power.
Some dementia research studies also use the AD8 as a screening tool to identify potential participants who need further evaluation. Caregiver support organizations and memory care facilities sometimes administer it as a routine check-in tool when families first seek services. The tool’s ease of administration and lack of cost make it accessible even in resource-limited healthcare settings, though in those contexts, interpretation may depend on the clinician’s expertise and access to follow-up diagnostic resources. It’s worth noting that while the AD8 is valuable, it is typically used alongside other screening methods rather than as a standalone tool, reflecting best practice in cognitive assessment.
The Future of Cognitive Screening and the AD8’s Role
As dementia research advances, screening tools like the AD8 are increasingly being integrated into digital platforms and clinical decision-support systems. Some healthcare systems now include the AD8 in electronic health records, allowing clinicians to track scores over time and identify cognitive decline trajectories. The tool’s simplicity makes it adaptable to different delivery formats—it can be administered in person, over the phone, or potentially through a patient portal, expanding its accessibility.
However, future directions in cognitive screening also include emerging biomarkers and advanced imaging, which may eventually provide earlier detection of dementia-related brain changes than behavioral assessment tools allow. The AD8 will likely remain a cornerstone of initial cognitive screening in clinical practice, even as complementary tools and biomarker approaches develop. Its value lies not just in diagnostic accuracy but in its practical utility: it’s a conversation starter between patients, families, and clinicians about cognitive health. As the population ages and awareness of dementia increases, having reliable, quick, accessible screening tools becomes ever more important, particularly in primary care where most older adults first encounter cognitive concerns.
Conclusion
The AD8 is a evidence-based, brief screening instrument that helps identify signs of dementia and mild cognitive impairment by capturing observations from people who know the person well. With sensitivity exceeding 84% and specificity exceeding 80%, it reliably signals when further cognitive evaluation is warranted, and its strong correlation with the Clinical Dementia Rating scale confirms its validity as a screening approach.
The tool’s simplicity, low cost, and practical applicability have made it a standard part of dementia evaluation protocols in clinical practice. If you or a family member are concerned about cognitive changes—whether forgetfulness that goes beyond normal aging, repeated questions, difficulty managing finances or medications, or noticeable functional decline—talking with your primary care physician about cognitive screening is an important first step. The AD8 may be one tool your doctor uses to determine whether comprehensive testing is needed, but regardless of the specific tool, early recognition of cognitive changes allows for timely evaluation, accurate diagnosis, and access to treatments and supports that can make a real difference.
You Might Also Like
- CDR Dementia Rating Explained
- CDR 3 Meaning: Severe Dementia Explained
- CDR 2 Meaning: Moderate Dementia Explained
For more, see Alzheimer’s Association.
